MYCBP and Miyoshi myopathy: Consistently, in this study, we highlighted the role of miR-22 as a bona fide endogenous MYC signaling inhibitor in MM, since its overexpression led to downregulation of, above MYC itself, several MYC cofactors, such MYCBP [39] and MAX [40], as well as MYC transcription activator, IKZF3.